CD200R agonist (ARQ-234)

Clinical landscape

• Atopic dermatitis is a common, chronic inflammatory skin disease affecting both children and adults²
• Itch is the most burdensome symptom, causing patients to experience substantially reduced quality of life and sleep disturbances³
• The skin barrier is typically compromised in atopic dermatitis⁴
• Topical corticosteroids and emollients are the standard of care⁴
• Steroids are not suitable for long-term use, and children are at risk of greater systemic absorption⁴

Proposed MOA

• CD200R is expressed by cells involved in type 2 inflammation⁵
• CD200R agonists activate the pathway that regulates immune cell activation¹
• ARQ-234 binds to CD200R, inducing inhibitory signaling on immune cells that regulate inflammation¹

MOA = mechanism of action